News

A Phase 1b clinical trial exploring the oral LRRK2 inhibitor DNL151 has started dosing Parkinson’s patients, the therapy’s developer Denali Therapeutics announced. The 28-day, multicenter, and double-blind study (NCT04056689) is testing two doses of DNL151 against placebo in people with mild to moderate Parkinson’s disease, and with or…

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded AC Immune a new grant to further the development of tracer compounds for Parkinson’s disease (PD). Specifically, this award continues MJFF support for AC Immune’s alpha-synuclein positron-emission tomography (PET) tracer program, aiming for an accurate imaging agent…

Trouble sleeping is incredibly frequent among people with Parkinson’s disease in Ethiopia, a new study suggests. Titled “Prevalence of sleep disorders in Parkinson’s disease patients in two neurology referral hospitals in Ethiopia,” the study was published in the journal BMC Neurology. Sleep disorders are common among…

Daily treatment with tablets of ENT-01, an investigational therapy for Parkinson’s disease, is safe and may restore patients’ bowel movements, according to results from Enterin‘s Phase 2a RASMET study. ENT-01 seems to locally stimulate a network of nerve cells that directs bowel function, suggesting that part of the nervous…